Travere Therapeutics (TVTX) Return on Invested Capital (2018 - 2026)

Travere Therapeutics' Return on Invested Capital history runs 8 years deep, the most recent figure standing at 0.01% for Q1 2026.

• Quarterly Return on Invested Capital rose 1.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY) and the FY2022 annual result came in at 0.44%, down 28.0% from the prior year.
• Return on Invested Capital was 0.01% for Q1 2026 at Travere Therapeutics, down from 0.0% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.0% in Q4 2025 and bottomed at 0.42% in Q1 2024.
• A 5-year average of 0.11% and a median of 0.12% in 2023 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2024 — Return on Invested Capital fell 30 bps — and 2025, when it jumped 40 bps.
• Travere Therapeutics' Return on Invested Capital stood at 0.11% in 2022, then slumped by 105 bps to 0.22% in 2023, then soared by 86 bps to 0.03% in 2024, then surged by 88 bps to 0.0% in 2025, then tumbled by 51 bps to 0.01% in 2026.
• Business Quant data shows TVTX's Return on Invested Capital at 0.01% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.